Skip to main content
Genscript Biotech Corporation logo

Genscript Biotech Corporation — Investor Relations & Filings

Ticker · 1548 ISIN · KYG3825B1059 LEI · 529900YIYUOJOXSAE372 HKEX Manufacturing
Open in API
Filings indexed 822 across all filing types
Latest filing 2016-04-26 Annual Report
Country KY Cayman Islands
Listing HKEX 1548

About Genscript Biotech Corporation

http://www.genscript.com/investor-relat…

Genscript Biotech Corporation is a world-leading technology and service provider specializing in life science research and manufacturing. The company offers a comprehensive portfolio of services and products essential for fundamental life science research, translational biomedical research, and early drug discovery and development. Core offerings include custom synthesis of genes, peptides, proteins, and antibodies, alongside molecular cloning and oligonucleotide production. GenScript also provides Contract Development and Manufacturing Organization (CDMO) solutions for innovative therapies through its specialized subsidiaries. The corporation leverages biotechnology and AI-driven approaches to advance life science solutions.

Recent filings

Filing Released Lang Actions
ANNUAL REPORT 2015
Annual Report Classification · 100% confidence The document is titled '2015 Annual Report' for Genscript Biotech Corporation and contains comprehensive sections typical of an annual report, including corporate profile, financial highlights, four-year financial summary, chairman's statement, management discussion and analysis, directors and senior management, corporate governance report, independent auditor's report, and detailed financial statements. The content covers the full fiscal year ended December 31, 2015, with detailed financial data and analysis. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. Therefore, this document fits the definition of an Annual Report (10-K).
2016-04-26 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2016
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 31/03/2016, submitted to the Hong Kong Exchanges and Clearing Limited. It details movements in authorised and issued share capital, share options, warrants, convertibles, and other share-related transactions. The content focuses on changes in share capital and securities movements rather than financial performance, earnings, or management commentary. It is a regulatory filing reporting share capital changes and securities movements for a specific month. This type of document fits best under 'Share Issue/Capital Change' (SHA) as it reports on share capital movements, share options exercised, and related capital changes.
2016-04-07 English
DISCLOSEABLE TRANSACTION: INVESTMENT AND COOPERATION AGREEMENT FOR INVESTMENT IN TARGET COMPANY
Capital/Financing Update Classification · 95% confidence The document is an announcement by Genscript Biotech Corporation regarding a discloseable transaction involving an investment and cooperation agreement to acquire a 51% equity interest in a target company. It details the terms of the investment, payment, conditions precedent, management structure post-investment, and financial information of the target company. The announcement references compliance with the Hong Kong Listing Rules, specifically Chapter 14 concerning discloseable transactions. The content is focused on a capital investment transaction and cooperation agreement, not a financial report, earnings release, or management discussion. It is a formal announcement of a capital/financing update related to the company's investment activities. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail confirm it is not a brief notice or a regulatory filing fallback. Confidence is high due to clear transaction details and regulatory references.
2016-04-06 English
Remuneration Committee - Terms of Reference
Remuneration Information Classification · 95% confidence The document is titled 'Remuneration Committee - Terms of Reference' and details the constitution, membership, duties, authority, and procedures of the Remuneration Committee of the Board of Directors. It focuses on the committee's role in determining and overseeing remuneration policies for directors and senior management. There are no financial statements, earnings data, or report publication announcements. The content is about governance and compensation policies rather than a report or announcement of financial results. This matches the definition of Remuneration Information filings, which detail compensation for top executives and directors.
2016-03-29 English
ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2015
Annual Report Classification · 100% confidence The document is titled 'ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2015' and contains detailed consolidated financial statements including profit or loss, comprehensive income, balance sheet, changes in equity, and cash flow statement for the full fiscal year ended December 31, 2015. It includes audited consolidated results and comparative figures for the previous year, as well as notes on accounting policies and basis of preparation. The length of the document (15,000 characters) and the presence of full financial data and analysis confirm it is a comprehensive annual financial report. This matches the definition of an Annual Report (10-K) rather than a short announcement or summary. Therefore, the correct classification is Annual Report (10-K).
2016-03-29 English
NOTICE OF BOARD MEETING
Regulatory Filings Classification · 95% confidence The document is an announcement from Genscript Biotech Corporation regarding the scheduling of a board meeting to consider and approve the annual results for the year ended 31 December 2015, as well as other business matters including dividend recommendations and share option schemes. The document is short (1923 characters) and does not contain any actual financial data or detailed results. It is essentially a notice about the timing and agenda of a board meeting rather than the annual report or financial results themselves. According to the rules, such announcements about meetings or report publication timing fall under Report Publication Announcement (RPA) or Regulatory Filings (RNS). Since this is specifically about a board meeting date and agenda, it fits best under Regulatory Filings (RNS) as a general regulatory announcement rather than a report publication announcement which usually states the report is attached or available. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2016-03-15 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.